Indications & Administration Guidelines

Who will benefit from RESPeRATE?

RESPeRATE was the first and remains the only medical device approved for the adjunctive treatment of hypertension in the US and was awarded the EU's Class 2A CE mark for medical devices. RESPeRATE can be used in combination with antihypertensive drugs, and/or non-pharmacologic interventions.

RESPeRATE is primarily recommended for patients who:

• Are aged 65+ with not-yet-at-target blood pressure - in spite of appropriate antihypertensive medication.
• Have diabetes with hypertension.
• Are diagnosed with isolated systolic hypertension.
• Have refractory hypertension.
• Refuse medication or experience side effects.

There are no known contraindications and have been no adverse reactions to the use of RESPeRATE. See detailed FDA indication for use

Administration Guidelines

• Patients should be instructed to use the RESPeRATE device routinely at rest, in 15-minute daily sessions, aiming to accumulate at least 40 minutes of slow breathing per week (10 breaths per minute or less).
• The weekly accumulated therapeutic time (minutes of slow breathing) appears on the device's display momentarily each time the device is turned on.
• Patients should be made aware that results, just like physical conditioning, may take a few weeks to become fully manifested and that without continued device use, any achieved benefits would likely be diminished.
• Studies show that the bulk of the reduction in BP occurs within 3 to 4 weeks of routine use.

See Resources >>